To make our work more visible and easier to follow, the personal Facebook profile of our founder, Sergei Oleshkevich, has now been opened to the public and set to Professional Mode. In addition to updates on our website, we will now also share selected project news, milestones, and progress updates on Facebook. This gives supporters and interested readers another simple way to follow the development of OncoHelper AI and our work in pediatric oncology.
In the four months since receiving official U.S. nonprofit status, OncoHelper AI has moved from formation into execution. Research teams are now in place for our three core programs, and work is underway: our AI platform, the zinc plus iron platform, and our PARP inhibitor program. We have reached the point where small early contributions unlock real momentum.
If you support better outcomes in pediatric oncology, your donation helps us keep the work moving forward.
We Expanded the Platform to Zinc Plus Iron
Over the past weeks, the project team substantially refined this program and strengthened the scientific and implementation plan. The project remains in development, but the architecture of the work is now clearly defined: a chickpea-derived peptide–mineral platform designed to deliver better-tolerated, more bioavailable supplementation for supportive care, starting with zinc.
A major update is that an iron track has been added to the program. In parallel with the zinc–peptide work, the team will identify and characterize iron-binding peptides from the same chickpea protein platform and define the stability and functional properties of peptide–iron complexes. This creates a practical foundation for future iron-focused formulations, using a shared production and deployment pathway.
Multiple technical discussions were held with professors and research collaborators from California-based universities and other partners to stress-test the plan, confirm feasibility, and tighten the milestone structure. The result is a more rigorous, better-scoped roadmap that links analytical characterization, absorption testing, functional bioactivity assays, and prototype formulation to clear, measurable deliverables.
We are now raising funding to launch laboratory execution and move through the first milestone series toward validated prototypes and regulatory-ready data packages.
We are launching this new project and beginning a six-month pilot phase. Our initial goals are to select a target protein system, set up a minimal quantitative assay stack for early phase behavior and aggregation signals, and complete the first intervention cycle with reproducible readouts and clear pilot milestones.
In parallel, we are engaging with potential research team members and partner laboratories. As these discussions progress, we will share the pilot scope, the first milestone package, and a clear collaboration pathway for laboratories and investigators who can contribute biophysical assays, cell-based validation, or modulator development.
While this pilot is not disease-specific, its ability to detect and steer early protein misfolding and aggregation could later support pediatric oncology by enabling earlier, more targeted intervention strategies where protein state changes contribute to treatment resistance and toxicity.
We are now fully verified on Benevity.
If your employer uses Benevity for workplace giving and matching gifts, you can support OncoHelper AI directly through your company’s giving portal. Many employers match employee donations, which can double or even triple the impact of your gift.
